Associate Professor of Radiology
Nuclear Medicine
Dr. Anca M. Avram, MD
|
|
Give Review
Anca Avram is an expert in the field of Nuclear Medicine. She received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Dr. Anca M. Avram is a published doctor and has 36 publications published. The lastest was: 'Potential Risks of Excess Iodine Ingestion and Exposure.' She is registered with Medicare.
Publications
- Potential Risks of Excess Iodine Ingestion and Exposure.
- Radioiodine Scintigraphy with SPECT/CT: An Important Diagnostic Tool for Thyroid Cancer Staging and Risk Stratification.
- Phase 1 study of radiosensitization using bortezomib in patients With relapsed non-Hodgkin lymphoma receiving radioimmunotherapy With (131)I-tositumomab.
- Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy.
- Thyroid Cancer in Children.
- Biological-Effect Modeling of RadioimmunOtherapy for Non-Hodgkins Lymphoma: Determination of Model Parameters.
- SPECT/CT Characterization of Oral Activity on Radioiodine Scintigraphy.
- SPECT/CT Evaluation of Unusual Physiologic Radioiodine Biodistributions: Pearls and Pitfalls in Image Interpretation.
- Preablation 131-I Scans With SPECT/CT in Postoperative Thyroid Cancer Patients: What Is the Impact on Staging?
- Residual Thyroid Tissue After Thyroidectomy in a Patient With TSH Receptor-Activating Mutation Presenting as a Neck Mass.
- Role of SPECT/CT, Versus Traditional Practices, in Individualizing Treatment of Thyroid Carcinoma: Reply.
- Prediction of therapy Tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.
- Three endocrine neoplasms: an unusual combination of pheochromocytoma, pituitary adenoma, and papillary Thyroid carcinoma.
- Three Endocrine Neoplasms: An Unusual Combination of Pheochromocytoma, Pituitary Adenoma and Papillary Thyroid Carcinoma.
- Radiation safety in the treatment of patients with Thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
- Comparison of single time-point [111-In] pentetreotide SPECT/CT With dual time-point imaging of neuroendocrine tumors.
- Adrenal cortical imaging with I-131 NP-59 SPECT-CT.
- Staging of differentiated Thyroid carcinoma using diagnostic 131I SPECT/CT.
- 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
- Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroEndocrine tumors.
- Use of integrated SPECT/CT imaging for Tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
- Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine.
- Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated Thyroid carcinoma.
- Posttherapy I-131 thymic uptake demonstrated with SPECT/CT in a young girl with papillary Thyroid carcinoma.
- Potential false positive Tc-99m sestamibi paraThyroid study due to uptake in brown adipose tissue.
- Sacral nerve root neurolymphomatosis diagnosed on FDG-PET/CT and magnetic resonance imaging.
- The so-called stunning of Thyroid tissue.
- Adrenal gland scintigraphy.
- Differentiation between carcinoid and sarcoid With F-18 FDG PET and In-111 pentetreotide.
- False-positive findings With positron emission tomography in the staging of non-small-cell lung cancer.
- Endogenous circulating ghrelin does not mediate growth hormone rhythmicity or response to fasting.
- FDG PET imaging features of epidermolysis bullosa complicated by squamous cell carcinoma.
- Choroidal and skin metastases from papillary Thyroid cancer: case and a review of the literature.
- The saddle sign: bilateral thigh adductor compartment uptake of Tc-99m MDP.
- Cryptococcal Thyroiditis and hyperThyroidism.
Schools
Universitatea De Medicina Si Farmacie Carol Davila Facultatea De Medicina
Fairview Hospital
University MiU Mi Med Center
Conditions Treated
- Abnormal Thyroid
- Adrenal Insufficiency
- Calcium Metabolism Disorders
- Diabetes Type 1
- View All
Doctors Specialties
- Nuclear Medicine
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Michigan Hospitals and Health Centers -
Carol Davila University of Medicine and Pharmacy
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1174616098 | |
| NPPES Provider LastName | AVRAM | |
| NPPES Provider FirstName | ANCA | |
| NPPES Provider ZIPCode | 481095028 | |
| NPPES Provider State | MI | |
| Specialty Description | Nuclear Medicine | |
| Total Claim Count | 188.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1174616098 |
| Last Name Of The Provider | AVRAM |
| First Name Of The Provider | ANCA |
| View All |
Similar Doctors
|
|
Dr. Milton D. Gross, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Morand R. Piert, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Raymond J. Whiteman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Theodore C. Marentis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hatice Savas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ka K. Wong, MB BS |